Evidence map›Paper›PMID 33151595›Full record

ReviewScandinavian journal of immunology2021

Paths taken towards NK cell-mediated immunotherapy of human cancer-a personal reflection.

Hans-Gustaf Ljunggren

Open access · hybridAbstract readReview
In one paragraph

Review in Scandinavian journal of immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Homotypic and heterotypicCurrent research in immunology · 2022
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Hans-Gustaf LjunggrenDepartment of Medicine, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0003-0908-7387
Karolinska Institutet · SE

Funding

European UnionKnut and Alice Wallenberg Foundation, Karolinska Institutet, Karolinska University HospitalNordstjernan ABRadiumhemmets ForskningsfonderRegion StockholmRoyal Swedish Academy of SciencesSwedish Cancer SocietySwedish Research CouncilTobias Foundation
6 · The paper itself

Abstract

The discovery that NK cells are able to specifically recognize cells lacking the expression of self-MHC class I molecules provided the first insight into NK cell recognition of tumour cells. It started a flourishing field of NK cell research aimed at exploring the molecular nature of NK cell receptors involved in tumour cell recognition. While much of the important early work was conducted in murine experimental model systems, studies of human NK cells rapidly followed. Over the years, human NK cell research has swiftly progressed, aided by new detailed molecular information on human NK cell development, differentiation, molecular specificity, tissue heterogeneity and functional capacity. NK cells have also been studied in many different diseases aside from cancer, including viral diseases, autoimmunity, allergy and primary immunodeficiencies. These fields of research have all, indirectly or directly, provided further insights into NK cell-mediated recognition of target cells and paved the way for the development of NK cell-based immunotherapies for human cancer. Excitingly, NK cell-based immunotherapy now opens up for novel strategies aimed towards treating malignant diseases, either alone or in combination with other drugs. Reviewed here are some personal reflections of select contributions leading up to the current state-of-the-art in the field, with a particular emphasis on contributions from our own laboratory. This review is part of a series of articles on immunology in Scandinavia, published in conjunction with the 50th anniversary of the Scandinavian Society for Immunology.

Indexed as

ImmunotherapyAnimalsAntigens, NeoplasmCell DifferentiationDisease Models, AnimalDisease SusceptibilityHistocompatibility Antigens Class IHost-Pathogen InteractionsHumansKiller Cells, NaturalLymphocyte ActivationNeoplasmsOrgan SpecificityReceptors, Antigen, T-CellTreatment OutcomeAntigens, NeoplasmHistocompatibility Antigens Class IReceptors, Antigen, T-CellcancerimmunotherapyMHC class Imissing-selfNK cellstumour immunity

Identifiers

PMID33151595
PMCPMC7816273
OpenAlexW3095145619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.